Bedrijfsoverzicht
Cryoport, Inc. is a specialized provider of temperature-controlled supply chain solutions that serves the biopharma, pharmaceutical, animal health, and reproductive medicine markets on a global scale. The company operates within the Industrials sector, specifically inside the Integrated Freight & Logistics industry, which necessitates rigorous adherence to strict cold-chain protocols to preserve the integrity of sensitive biological products. As of the latest data, the enterprise holds a market capitalization of $484.17M and employs a workforce of 684 individuals to support its logistical operations. With annual revenue reaching $176.18M, the company maintains a mid-cap profile that reflects a solid operational footprint but suggests it is still consolidating its position against larger industry peers. The combination of a $484.17M market cap and $176.18M in revenue indicates that while the firm has established a significant presence in the life sciences logistics space, it remains a smaller player relative to the massive revenue streams generated by global freight giants. This scale allows Cryoport to offer niche cryopreservation and bioservices while managing the high fixed costs associated with maintaining a global network of refrigerated facilities.
Financiële gezondheid
The company reported a Trailing Twelve Months (TTM) revenue of $176.18M, yet it recorded a net income of $-41,969,000, highlighting a substantial gap between top-line growth and bottom-line profitability. This significant divergence between revenue and net income reveals a cost structure where operating expenses, likely driven by fuel, refrigeration technology, and labor, are outpacing gross profit generation, resulting in a net loss despite healthy sales figures. The firm generated an EBITDA of $-3,916,000, which further underscores the ongoing challenges in covering its core operational costs before interest and taxes. Free cash flow stands at $-396,125, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility for capital expenditures or debt repayment without external funding. Despite the losses, the balance sheet shows a robust cash position of $411.21M, which is more than double the total debt of $230.72M, suggesting a conservative liquidity stance for a company currently in a growth or restructuring phase. The debt-to-equity ratio of 45.90 indicates a leveraged balance sheet, but the high cash reserves provide a substantial buffer against this debt load. Liquidity is further supported by a current ratio of 2.17, which signifies that the company holds 2.17 times more current assets than current liabilities, ensuring it can easily meet its short-term obligations. However, the Return on Equity of -7.5% and Return on Assets of -2.7% reveal that management is currently unable to generate positive returns on the capital invested by shareholders or deployed across its asset base, pointing to operational inefficiencies or the high initial investment costs typical in the cryogenic logistics sector.
Waarderingsbeoordeling
Valuation metrics for Cryoport present a complex picture given the company's unprofitable status, with a trailing P/E ratio listed as N/A and a forward P/E of -16.96. The negative forward P/E implies that the market is pricing in a trajectory where earnings are expected to remain negative or that traditional earnings-based valuation models are not applicable at this stage of the company's lifecycle. The price-to-book ratio is 1.05, indicating that the market values the company at a slight premium over its tangible book value, suggesting investors are paying for intangible assets like the logistics network or future growth potential. Alternative valuation multiples such as the price-to-sales ratio of 2.75 and an EV/EBITDA of -87.82 provide further insight, with the high P/S ratio reflecting the market's willingness to pay for revenue growth despite the lack of current earnings. The stock trades between a 52-week high of $11.45 and a 52-week low of $5.21, meaning the current share price sits at a level that reflects significant volatility and sensitivity to broader market sentiment regarding biopharma logistics. The beta of 1.69 indicates that the stock is highly volatile, moving with 1.69 times the magnitude of the broader market, which suggests that investors face higher price fluctuations than those holding the general market index.
Growth & Income
Cryoport demonstrated a revenue growth year-over-year of 9.6%, while earnings growth is N/A due to the company's ongoing losses. The fact that revenue is growing while earnings remain negative implies that the company is investing heavily in capacity or operations to capture market share, prioritizing top-line expansion over immediate profitability. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all earnings are theoretically available for reinvestment, though currently, the company is operating at a net loss. This reinvestment strategy is typical for growth-stage logistics firms that must expand their cold-chain infrastructure to meet the surging demand for temperature-sensitive biopharmaceuticals. The overall growth and income profile is defined by strong revenue expansion offset by significant operational losses, with no current income distribution to shareholders. The absence of dividend payments combined with a high beta suggests the asset is purely speculative for income-focused investors and is driven entirely by expectations of future earnings normalization.